Content area
Full Text
The University of Maryland has picked Antex Biologics to develop and market a new class of antibiotic compounds. These new compounds have proved to kill disease-causing bacteria in labs, and the partnership could lead to new drugs for Gaithersburg-based Antex.
AntexPharma, a subsidiary of Antex (www.antexbiologics. com), will manage preclinical and clinical development of the antibiotics, and the College Park school (www.umcp.umd.edu) will receive royalty payments once regulatory approval and commercialization are achieved.
Antex officials hope the agreement, coupled with other projects the biopharmaceutical company is working on, will help elevate the company's sagging stock performance.
"The collaboration is quite significant for us," says President Stephen Keith.
Antex stock...